A point mutation in the c-myc locus of a Burkitt lymphoma abolishes binding of a nuclear protein.
A 20-base pair region in the first intron of the human c-myc gene was identified as the binding site of a nuclear protein. This binding site is mutated in five out of seven Burkitt lymphomas sequenced to date. To investigate the protein-recognition region in greater detail, the abnormal c-myc allele from a Burkitt lymphoma line (PA682) that carries a t(8;22) chromosomal translocation was used. A point mutation in the binding region of the PA682 c-myc DNA abolished binding of this nuclear protein. This protein may be an important factor for control of c-myc expression, and mutations in its recognition sequence may be associated with c-myc activation in many cases of Burkitt lymphoma.
Zajac-Kaye
M
M
Medicine Branch, National Cancer Institute, Bethesda, MD 20892.
Gelmann
E P
EP
Levens
D
D
D001483:Base Sequence; D002051:Burkitt Lymphoma / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005786:Gene Expression Regulation; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D009687:Nuclear Proteins / Q000378:metabolism*; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012313:RNA / Q000235:genetics; D016372:RNA, Antisense; D014158:Transcription, Genetic
D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016372:RNA, Antisense; D012313:RNA